What is Primary hyperoxaluria?
Primary hyperoxaluria (PH) is a rare inherited disorder that causes the body to produce too much oxalate, a waste product normally eliminated through urine. This excess oxalate combines with calcium to form crystals that damage the kidneys and other organs. The condition affects approximately 1-3 people per million worldwide, making it an ultra-rare disease. Primary hyperoxaluria type 1 (PH1) is the most common and severe form, accounting for about 80% of all cases.
Key statistics
| Prevalence | 1-3 per million people worldwide |
| Carrier frequency | Approximately 1 in 70 people (estimated) |
| Age of onset | Infancy to adulthood; 50% diagnosed before age 5 |
| Kidney failure risk | 50% develop end-stage renal disease by age 15 |
Symptoms
Common symptoms: Recurrent kidney stones, blood in urine, severe abdominal or back pain, frequent urination, nausea, vomiting, failure to thrive in children.
The hallmark symptom of primary hyperoxaluria is recurrent calcium oxalate kidney stones, often beginning in childhood. These stones cause excruciating pain in the back, side, or lower abdomen that may radiate to the groin. Patients frequently experience blood in their urine (hematuria), which may appear pink, red, or brown. Nephrocalcinosis—calcium deposits in the kidney tissue—develops as the condition progresses.
In infants and young children, symptoms may include failure to thrive, irritability, frequent urination, and signs of kidney dysfunction. As kidney function deteriorates, patients may develop high blood pressure, swelling in the legs and feet, fatigue, and decreased urine output. In advanced stages, oxalate crystals can deposit throughout the body (systemic oxalosis), affecting bones, joints, eyes, heart, and skin, causing bone pain, fractures, vision problems, and skin lesions.
Causes and risk factors
Primary hyperoxaluria is caused by mutations in genes responsible for oxalate metabolism in the liver. PH1, the most severe form, results from mutations in the AGXT gene, which provides instructions for making the enzyme alanine-glyoxylate aminotransferase. This enzyme normally converts glyoxylate to glycine in liver cells, but when deficient, glyoxylate is instead converted to oxalate.
The condition follows an autosomal recessive inheritance pattern, meaning both parents must carry a mutated gene copy for a child to be affected. Each child of carrier parents has a 25% chance of having the condition, a 50% chance of being a carrier, and a 25% chance of inheriting normal genes.
Risk factors include having parents who are carriers, particularly in populations with higher carrier frequencies due to founder effects or consanguinity. There are no known environmental risk factors, as this is purely a genetic condition.
Prevention
Primary hyperoxaluria cannot be prevented as it is an inherited genetic condition. However, genetic counseling and testing can help families understand their risk and make informed reproductive decisions. Carrier testing is available for at-risk family members, and preimplantation genetic diagnosis (PGD) can be used during in vitro fertilization to select unaffected embryos.
Prenatal genetic testing through amniocentesis or chorionic villus sampling can diagnose the condition during pregnancy if both parents are known carriers. Early diagnosis through newborn screening programs, where available, can lead to prompt treatment and better outcomes.
Complications
Without proper treatment, primary hyperoxaluria leads to progressive kidney damage and eventual kidney failure. The continuous formation of calcium oxalate crystals causes chronic kidney inflammation, scarring, and loss of function. Most patients with PH1 develop chronic kidney disease, with 50% progressing to end-stage renal disease requiring dialysis or transplantation by age 15.
As kidney function declines, oxalate accumulates in the blood and deposits throughout the body, causing systemic oxalosis. This can lead to bone disease, fractures, joint problems, heart rhythm abnormalities, blood vessel damage, retinal deposits affecting vision, and painful skin lesions. Bone marrow involvement can cause anemia, while deposits in the nervous system may lead to seizures or stroke.
Diagnosis
Diagnosis begins with measuring oxalate levels in 24-hour urine collections, with elevated levels (>0.5 mmol/day or >45 mg/day) suggesting hyperoxaluria. Imaging studies including ultrasound, CT scans, or X-rays can detect kidney stones, nephrocalcinosis, and structural kidney damage.
Genetic testing is the definitive diagnostic method, identifying mutations in the AGXT gene for PH1. Enzyme activity testing in liver biopsy samples can confirm enzyme deficiency, though this is rarely performed due to the availability of genetic testing. Additional tests include kidney function assessment through serum creatinine and estimated glomerular filtration rate, complete blood count, electrolyte panels, and specialized imaging like DEXA scans to evaluate bone health.
Crystal analysis of kidney stones typically reveals calcium oxalate monohydrate crystals. Family history and genetic counseling are important components of the diagnostic process.
Treatment
Treatment aims to reduce oxalate production and prevent kidney damage. Lumasiran is a groundbreaking RNA interference therapy approved for PH1 that reduces oxalate production by targeting the LDHA enzyme. Nedosiran is another RNAi therapy in development showing promising results.
Pyridoxine (vitamin B6) supplementation helps some patients by increasing residual enzyme activity. High fluid intake (3-4 liters daily) helps dilute urine and reduce crystal formation. Potassium citrate alkalinizes urine and inhibits crystal formation, while magnesium supplements can bind oxalate in the intestines.
For patients with kidney failure, dialysis provides temporary oxalate removal, but liver transplantation is often necessary to correct the underlying enzyme deficiency. Combined liver-kidney transplantation may be required for patients with both liver enzyme deficiency and kidney failure. Kidney transplantation alone is generally avoided in PH1 due to high recurrence rates.
Prognosis
The prognosis for primary hyperoxaluria has significantly improved with new treatments and early diagnosis. Historically, PH1 carried a poor prognosis, with most patients developing kidney failure in childhood. With current therapies like lumasiran and aggressive supportive care, many patients can maintain kidney function and avoid dialysis.
Early treatment initiation is crucial for preserving kidney function. Patients diagnosed and treated before significant kidney damage occurs have the best outcomes. Even with treatment, regular monitoring is essential as the condition requires lifelong management. Successful liver transplantation can cure the underlying metabolic defect, leading to normal oxalate levels and preventing further organ damage.
Quality of life
Living with primary hyperoxaluria requires significant lifestyle adaptations but many patients maintain good quality of life with proper management. Adequate hydration is crucial—patients must drink large volumes of fluids throughout the day and night, which can disrupt sleep and daily activities.
Dietary modifications include limiting high-oxalate foods like spinach, rhubarb, nuts, chocolate, and tea. Regular exercise is encouraged but should be balanced with increased fluid intake to prevent dehydration. Patients often experience anxiety related to kidney stone episodes and the chronic nature of their condition, making mental health support important.
Educational and workplace accommodations may be needed for frequent medical appointments, dietary restrictions, and bathroom breaks. Support groups and patient communities provide valuable emotional support and practical advice for managing daily challenges.
Pregnancy and fertility
Primary hyperoxaluria can complicate pregnancy due to increased kidney stress and the need for adequate hydration. Women with PH should receive pre-conception counseling to optimize kidney function and medication management. Pregnancy may worsen kidney function and increase stone formation risk due to hormonal changes and increased calcium excretion.
Genetic counseling is essential, as each pregnancy carries a 25% risk if the partner is also a carrier. The safety of newer treatments like lumasiran during pregnancy is not yet established, requiring careful risk-benefit discussions. Close monitoring by maternal-fetal medicine specialists and nephrologists is recommended throughout pregnancy.
Children
Primary hyperoxaluria often presents in infancy or early childhood with failure to thrive, recurrent infections, or kidney stones. Pediatric management focuses on preserving kidney function through aggressive fluid therapy, dietary modifications appropriate for growth needs, and family education.
Children require age-appropriate explanations of their condition and involvement in their care as they mature. School accommodations may be needed for frequent bathroom breaks, fluid intake, and medical appointments. Growth and development monitoring is essential, as chronic kidney disease can affect both. Early intervention with newer therapies like lumasiran offers hope for preventing kidney damage in pediatric patients.
When to see a doctor
Seek immediate medical attention for severe abdominal or back pain, blood in urine, inability to urinate, fever with urinary symptoms, or signs of kidney stones. These symptoms may indicate stone blockage or infection requiring urgent treatment.
Schedule routine care for family history of kidney stones in children, recurrent kidney stones, chronic kidney disease of unknown cause, or if genetic testing reveals carrier status. Regular follow-up is essential for diagnosed patients to monitor kidney function, adjust treatments, and prevent complications.
Regional context
Limited data exists on primary hyperoxaluria prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. The condition’s rarity makes regional epidemiological studies challenging, though isolated case reports suggest it occurs worldwide across all ethnic groups.
Founder effects in isolated populations may lead to higher local prevalence rates. We encourage regional medical communities to contribute their experience with primary hyperoxaluria to the Global Medical Journal to better understand the condition’s geographic distribution and improve care in underserved areas.
Research and clinical trials
Research in primary hyperoxaluria has accelerated dramatically with RNA interference therapies showing remarkable promise. Lumasiran has demonstrated 65% reduction in urinary oxalate levels in clinical trials. Nedosiran, targeting a different pathway, shows similar efficacy and is progressing through clinical development.
Gene therapy approaches are under investigation, potentially offering permanent correction of the enzyme deficiency. Researchers are also exploring substrate reduction therapy, alternative enzyme replacement strategies, and improved dialysis techniques for oxalate removal.
Current clinical trials can be found at ClinicalTrials.gov using search terms “primary hyperoxaluria” or “PH1.” Patients should discuss trial participation with their physicians, as access to experimental treatments may be available through compassionate use programs.
Frequently asked questions
Is primary hyperoxaluria inherited from both parents?
Yes, PH1 follows autosomal recessive inheritance, requiring mutated genes from both parents. Each child has a 25% risk of being affected if both parents are carriers.
Can dietary changes alone manage primary hyperoxaluria?
No, dietary oxalate restriction and increased fluid intake are helpful supportive measures, but they cannot adequately reduce the massive oxalate overproduction in PH1. Specific medications are necessary.
How effective are the new RNA therapies?
Lumasiran reduces urinary oxalate levels by approximately 65% in clinical trials, representing a major breakthrough. Many patients experience significant symptom improvement and kidney function stabilization.
Can kidney transplantation cure primary hyperoxaluria?
Kidney transplantation alone cannot cure PH1 because the liver continues producing excess oxalate, which can damage the new kidney. Liver transplantation or liver-kidney transplantation addresses the underlying enzyme deficiency.
What is the life expectancy with proper treatment?
With early diagnosis and current treatments, life expectancy approaches normal. Historical data showed poor outcomes, but new therapies like lumasiran have dramatically improved the prognosis for patients with preserved kidney function.
Support and resources
Oxalosis & Hyperoxaluria Foundation (OHF)
Website: ohf.org
Comprehensive patient resources, research updates, and community support.
National Organization for Rare Disorders (NORD)
Website: rarediseases.org
Rare disease information and advocacy resources.
Orphanet
Website: orpha.net
European database of rare diseases and orphan drugs.
EURORDIS (European Organisation for Rare Diseases)
Website: eurordis.org
European rare disease patient advocacy and support.
Related conditions
Secondary hyperoxaluria
Chronic kidney disease
Nephrolithiasis
Cystinuria
Wilson disease
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Primary hyperoxaluria.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/primary-hyperoxaluria/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?